Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Phase 3 Not yet recruiting 20 enrolled Alexion Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).

Timeline

Start: 2026-07-30
Primary completion: 2027-08-27
Completion: 2027-08-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ravulizumab	Monoclonal antibody	—	Intravenous

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Summary

Timeline

Drugs

Indications